News from AHA 2024: spironolactone post-MI

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Presenters

Overview
AHA 2024 - Sanjit Jolly shares the spironolactone factorial results of the CLEAR SYNERGY (OASIS 9) trial, in which routine use of spironolactone did not reduce the risk of the two co-primary endpoints after an MI.
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Sanjit Jolly, MD is an interventional cardiologist at Hamilton Health Sciences and associate professor at McMaster University in Hamilton, ON, Canada.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of this study were simultaneously published in N Eng J Med.
Release date: 20 November 2024

Recommended

Details

Presenters

Overview
AHA 2024 - Sanjit Jolly shares the spironolactone factorial results of the CLEAR SYNERGY (OASIS 9) trial, in which routine use of spironolactone did not reduce the risk of the two co-primary endpoints after an MI.
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Sanjit Jolly, MD is an interventional cardiologist at Hamilton Health Sciences and associate professor at McMaster University in Hamilton, ON, Canada.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of this study were simultaneously published in N Eng J Med.
Release date: 20 November 2024

No benefit of routine spironolactone post-MI